Judith Maxwell Silverman

Title: Judith Maxwell Silverman: Innovator in Antibody Research

Introduction

Judith Maxwell Silverman is a prominent inventor based in Whistler, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies targeting amyloid-beta (A-beta) oligomers. Her innovative work has the potential to impact therapeutic approaches for neurodegenerative diseases.

Latest Patents

Judith holds 2 patents related to her research. Her latest patents include:

1. **Humanized antibodies binding to amyloid-beta (A-beta)** - This patent discloses antibodies that bind A-beta oligomers and outlines methods for making and using these antibodies. It also includes chimeric or humanized antibodies, featuring specific CDR sequences and methods of application.

2. **Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers** - This patent focuses on antibodies that bind A-beta oligomers and details methods for their production and use.

Career Highlights

Judith has worked with notable institutions, including the University of British Columbia and Promis Neurosciences Inc. Her research has been pivotal in advancing our understanding of amyloid-beta and its implications in neurodegenerative diseases.

Collaborations

Throughout her career, Judith has collaborated with esteemed colleagues such as Neil R. Cashman and Steven S. Plotkin. These partnerships have enriched her research and contributed to the development of innovative solutions in her field.

Conclusion

Judith Maxwell Silverman is a trailblazer in antibody research, with a focus on addressing the challenges posed by amyloid-beta in neurodegenerative diseases. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.